SNSE — Sensei Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1829802 ·
Last close
$16.47
Market Cap
$22.10M
52W High
$36.07
52W Low
$16.07
ADV30
31,354
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -170,627,000 | -170,236,000 | 205,381,000 | 152,325,000 | 342,667,000 |
| Dec 2025 | 0 | — | -4,957,000 | -4,717,000 | 22,902,000 | 8,668,000 | 4,310,000 |
| Sep 2025 | 0 | — | -4,851,000 | -4,569,000 | 27,589,000 | 10,562,000 | 4,582,000 |
| Jun 2025 | 0 | — | -5,206,000 | -4,936,000 | 31,783,000 | 12,557,000 | 4,469,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,453,000
Investing CF
$19,772,000
Financing CF
$-645,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-18.73
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,137,000
Inventory
—
Receivables
—
ST Investments
$12,516,000
EBIT TTM
$-21,054,000
Pretax Income TTM
$-21,086,000
Interest Exp TTM
$32,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,288,000 | -21,085,000 | 22,902,000 | 4,310,000 | — | -20,453,000 |
| Dec 2024 | 0 | -31,663,000 | -30,157,000 | 45,361,000 | 6,975,000 | — | -24,670,000 |
| Dec 2023 | 0 | -37,064,000 | -34,101,000 | 74,374,000 | 9,479,000 | — | -32,023,000 |
| Dec 2022 | 0 | -50,188,000 | -48,588,000 | 118,375,000 | 14,968,000 | — | -39,026,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.97
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | $22.51M | $0.46 | — |
| VYNE | VYNE Therapeutics Inc. | $22.66M | $0.68 | — |
| KTTA | Pasithea Therapeutics Corp. | $22.73M | $0.68 | — |
| AYTU | AYTU BIOPHARMA, INC | $23.40M | $2.18 | — |
| TRAW | Traws Pharma, Inc. | $23.94M | $1.58 | — |
News headlines (Yahoo Finance, 1h cache)
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:30 · Yahoo
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts
2026-05-05 17:06 · Yahoo
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
2026-05-05 11:30 · Yahoo
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-09 11:30 · Yahoo
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-03-30 11:30 · Yahoo
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-17 10:00 · Yahoo
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
2026-02-18 13:00 · Yahoo
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
2026-01-07 13:00 · Yahoo
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
2025-11-14 12:30 · Yahoo
Sensei to ditch its lead candidate and cut workforce amidst strategic review
2025-10-31 18:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.